2024 A Focus on Genitourinary Cancers

aci-genitourinary-cancers_-_Edited.png

tuesday, june 11, 2024 | 11 A.m.-3 P.M. ET
Live via Zoom Webinar

Register Now


Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for genitourinary cancers. FREE for healthcare professionals, students, patients and patient advocates.

Cancer Immunotherapy in Practice will address holistic care for patients receiving immunotherapy, from educating patients and their families to toxicity management and other clinical considerations.

The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Program Organizers

Rohan Garje, MD
Miami Cancer Institute

Moshe Ornstein, MD, MA
Cleveland Clinic

Risa L. Wong, MD
UPMC

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Tuesday, June 11, 2024 at 11 a.m-3 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Genitourinary Cancers >

Program Agenda

11–11:05 a.m.

 

Welcome and Relevant SITC Resources

11:05–11:45 a.m.

 

Immunotherapy for Kidney Cancer
Rana McKay, MD – University of California San Diego

11:45 a.m.–
12:25 p.m.

 

Immunotherapy for Bladder Cancer
Srikala Sridhar, MD – Princess Margaret Cancer Center

12:25–12:45 p.m.

 

Immunotherapy for Prostate Cancer
Risa L. Wong, MD – UPMC

12:45–1:05 p.m.

 

Immunotherapy for Rare GU Tumors
Brad McGregor, MD – Dana-Farber Cancer Institute

1:05–1:20 p.m.

 

Break

1:20–2 p.m.

 

Cancer Immunotherapy in Practice: Preparing patients and family members for immunotherapy
Rohan Garje, MD – Miami Cancer Institute

Allison Martin, PA-C – Cleveland Clinic

2–3 p.m.

 

Faculty Panel

3 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches in use for the treatment of genitourinary cancers.
  • Summarize recent updates in cancer immunotherapy for genitourinary cancers including emerging toxicities and management.
  • Implement cancer immunotherapy for genitourinary cancer into clinical practice appropriately.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

 

Disclosures

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

SITC's Clinical Practice Guideline (CPG) Resources

Find information regarding disease-specific treatment algorithms and recommended administration of FDA-approved cancer immunotherapies. The guidelines are reviewed by expert panels on a recurring basis to account for newly available clinical trial data and FDA approvals.